Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics
GET POWR RATINGS... FREE!
RANI Stock Price Chart Interactive Chart >
RANI Price/Volume Stats
| Current price | $5.78 | 52-week high | $19.39 |
| Prev. close | $5.55 | 52-week low | $5.11 |
| Day low | $5.60 | Volume | 56,697 |
| Day high | $5.89 | Avg. volume | 35,172 |
| 50-day MA | $6.74 | Dividend yield | N/A |
| 200-day MA | $9.11 | Market Cap | 285.30M |
Rani Therapeutics Holdings, Inc. (RANI) Company Bio
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Latest RANI News From Around the Web
Below are the latest news stories about RANI THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle ConferenceORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company''s participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom. Gareth Sheridan, Nutriband''s CEO, will give a presentation at 11:00 a.m. GMT on January 24 th entitled ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications'' which will provide an overview of the development of transdermal drug delivery systems using Nutriband''s AVERSA technology as a reference point. Nutriband COO and President of its 4P Therapeutics subsidiary, ... |
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody TreatmentCelltrion will be Rani’s exclusive supplier of ustekinumab biosimilar, CT-P43, for oral RT-111 RaniPill™ programSAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar. Under a license and supply agr |
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it completed a |
Rani Therapeutics Lead Program Achieves Endpoints In Repeat-Dose Part Of Osteoporosis StudyRani Therapeutics Holdings Inc (NASDAQ: RANI ) announced topline results from Part 2 (repeat-dose portion) of the Phase 1 study of RT-102 for osteoporosis. RT-102, the RaniPill GO capsule, contains a proprietary formulation of human parathyroid hormone (1-34) analog (PTH). The study achieved all of its endpoints, with repeat doses of RT-102 being … Full story available on Benzinga.com |
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and Part 2 of the Phase 1 study of RT-102 support advancement to a Phase 2 study – - Company to host conference call today at 4:30 pm ET / 1:30 pm PT - SAN JOSE, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE |
RANI Price Returns
| 1-mo | -11.08% |
| 3-mo | -11.21% |
| 6-mo | -47.95% |
| 1-year | -69.97% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -2.03% |
| 2022 | -63.91% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...